Domestic pharmaceutical firms grappling with sales target in first half

Korean consumers grew more pessimistic about the economy in recent months, deepening the gloom surrounding tepid domestic demand, which prompted many pharmaceutical makers, including Daewoong and Boryung Pharm, to increase the pricing of their main OTC products in line with a variety of incentives.

Indeed, a domestic pharmaceutical maker garnered its five-month sales of 18 billion won, of wh...